Inhibition of K

KCa2 channel inhibitor Kv11.1 blockers SK channel SK channel inhibitor antiarrhythmic drug arrhythmia dofetilide hypokalemia

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2020
Historique:
received: 26 02 2020
accepted: 06 05 2020
entrez: 9 6 2020
pubmed: 9 6 2020
medline: 9 6 2020
Statut: epublish

Résumé

Hypokalemia reduces the cardiac repolarization reserve. This prolongs the QT-interval and increases the risk of ventricular arrhythmia; a risk that is exacerbated by administration of classical class 3 anti-arrhythmic agents.Small conductance Ca To study the effects of pharmacological K The current at +10 mV was compared in HEK293 cells stably expressing K Hypokalemia slightly increased K Hypokalemia was associated with an increased incidence of VF, an effect that also seen in the presence of dofetilide. In comparison, the structurally and functionally different K

Sections du résumé

BACKGROUND BACKGROUND
Hypokalemia reduces the cardiac repolarization reserve. This prolongs the QT-interval and increases the risk of ventricular arrhythmia; a risk that is exacerbated by administration of classical class 3 anti-arrhythmic agents.Small conductance Ca
PURPOSE OBJECTIVE
To study the effects of pharmacological K
METHODS METHODS
The current at +10 mV was compared in HEK293 cells stably expressing K
RESULTS RESULTS
Hypokalemia slightly increased K
CONCLUSION CONCLUSIONS
Hypokalemia was associated with an increased incidence of VF, an effect that also seen in the presence of dofetilide. In comparison, the structurally and functionally different K

Identifiants

pubmed: 32508659
doi: 10.3389/fphar.2020.00749
pmc: PMC7251152
doi:

Types de publication

Journal Article

Langues

eng

Pagination

749

Informations de copyright

Copyright © 2020 Diness, Abildgaard, Bomholtz, Skarsfeldt, Edvardsson, Sørensen, Grunnet and Bentzen.

Références

Cardiovasc Res. 2014 Jul 1;103(1):156-67
pubmed: 24817686
J Am Heart Assoc. 2013 Jan 03;2(1):e004713
pubmed: 23525437
Pflugers Arch. 1992 Feb;420(2):180-6
pubmed: 1620577
Circ Res. 2011 Apr 15;108(8):971-9
pubmed: 21350217
Annu Rev Physiol. 1997;59:171-91
pubmed: 9074760
Circ Arrhythm Electrophysiol. 2017 Oct;10(10):
pubmed: 29018164
Am J Physiol Heart Circ Physiol. 2012 Mar 1;302(5):H1023-30
pubmed: 22159993
Cardiovasc Res. 2003 Apr 1;58(1):32-45
pubmed: 12667944
J Pharmacol Toxicol Methods. 2014 Jan-Feb;69(1):61-101
pubmed: 23689033
Circulation. 2015 Oct 20;132(16):1528-1537
pubmed: 26269574
J Cardiovasc Pharmacol. 2015 Sep;66(3):294-9
pubmed: 25978690
Heart Rhythm. 2013 Oct;10(10):1516-24
pubmed: 23835258
Cardiovasc Res. 1995 Jul;30(1):31-8
pubmed: 7553721
Circ Arrhythm Electrophysiol. 2017 Mar;10(3):
pubmed: 28314851
Circ Res. 2020 Mar 27;126(7):889-906
pubmed: 32070187
Exp Physiol. 2009 Apr;94(4):434-46
pubmed: 19151074
Am J Med. 2015 Jan;128(1):60-7.e1
pubmed: 25107385
Front Pharmacol. 2020 Feb 28;11:159
pubmed: 32180722
Acta Physiol (Oxf). 2009 Dec;197(4):273-87
pubmed: 19656123
Front Pharmacol. 2019 Jun 19;10:668
pubmed: 31275147
Heart Rhythm. 2015 Apr;12(4):825-35
pubmed: 25542425
Pflugers Arch. 2017 Jun;469(5-6):739-750
pubmed: 28285409
Biophys J. 2001 May;80(5):2207-15
pubmed: 11325723
J Physiol. 2015 Mar 15;593(6):1509-21
pubmed: 25772299
Br Heart J. 1984 Feb;51(2):157-62
pubmed: 6197982
Circ Arrhythm Electrophysiol. 2010 Aug;3(4):380-90
pubmed: 20562443
PLoS One. 2014 Oct 01;9(10):e108824
pubmed: 25271970
Circulation. 2015 Oct 13;132(15):1377-86
pubmed: 26362634
Am J Physiol Heart Circ Physiol. 2013 Jan 1;304(1):H118-30
pubmed: 23086994
Circulation. 2014 Jan 28;129(4):430-40
pubmed: 24190961
Circ Res. 1997 Jun;80(6):782-9
pubmed: 9168780

Auteurs

Jonas Goldin Diness (JG)

Acesion Pharma, Copenhagen, Denmark.

Lea Abildgaard (L)

Acesion Pharma, Copenhagen, Denmark.

Sofia Hammami Bomholtz (SH)

Acesion Pharma, Copenhagen, Denmark.
Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Mark Alexander Skarsfeldt (MA)

Acesion Pharma, Copenhagen, Denmark.
Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Nils Edvardsson (N)

Acesion Pharma, Copenhagen, Denmark.
Department of Molecular and Clinical Medicine/Cardiology, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Ulrik S Sørensen (US)

Acesion Pharma, Copenhagen, Denmark.

Morten Grunnet (M)

Acesion Pharma, Copenhagen, Denmark.

Bo Hjorth Bentzen (BH)

Acesion Pharma, Copenhagen, Denmark.
Department of Molecular and Clinical Medicine/Cardiology, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Classifications MeSH